Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-03
2008-12-02
Kemmerer, Elizabeth C (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S085100, C435S069100
Reexamination Certificate
active
07459426
ABSTRACT:
Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is a molecule capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), or systemic onset juvenile idiopathic arthritis (Still's Disease).
REFERENCES:
patent: 6927044 (2005-08-01), Stahl et al.
patent: 2001/0053764 (2001-12-01), Sims et al.
patent: 2003/0143697 (2003-07-01), Stahl et al.
patent: 2005/0129685 (2005-06-01), Cao et al.
patent: WO 2004/022718 (2004-03-01), None
Galeazzi et al., Clin. Exp. Rheumatol., 2006, 24(1 Suppl. 40):S79-85 (abstract).
Rotondi et al., Endocri. Rev., 2007, 28(5): 492-520.
Aksentijevich, I., et al. (2002) Arthritis & Rheumatism, vol. 46, No. 12, pp. 3340-3348.
Pascual, V., et al. (2005) JEM The Rockefeller University Press, vol. 201, No. 9, pp. 1479-1486.
Stehlik, C., et al. (2004) J. Exp. Med. The Rockefeller University Press, vol. 200, No. 5, pp. 551-558.
Dinarello, C.A., (2005) JEM The Rockefeller University Press, vol. 201, No. 9, pp. 1355-1359.
Hawkins, P.N., et al. (2004) Arthritis & Rheumatism, vol. 50, No. 2, pp. 607-612.
Hoffman, H.M., et al. (2004) Arthritis & Rheumatism, vol. 50, No. 2, pp. 345-349.
Amgen, Inc.—Kineret™ (anakinra) Prescribing Instructions, Dec. 15, 2006.
Canna, S. et al. (2005) Treatment of 4 Patients wiht Cryoporin-Associated Periodic . . . Arthritis & Rheumatism 52(9, Suppl) :Abstract 672.
Carter, John D. et al. (2003) Letters to the Editor: Crohn Disease Worsened by Anakinra Administration, J. Clin. Rheumatology 9(4) :276-277.
Hawkins, P.N. et al. (2003) Letter: Interleukin-1 Receptor Antagonist in Muckle-Wells Syndrome, N. Eng. J. Med. 348:2583-2584.
Lovell, D. J. (2007) Preliminary Evidence for . . . Bioactivity of IL-1 Trap . . . in SJIA, Arthritis & Rheumatism, 56(9, Suppl) :S514, Abstract 1282.
Shroff, S. et al. (2007) Safety and Efficacy of IL-1 Trap in Patients with Familial . . . Arthritis & Rheumatism, 56(9, Suppl) :S365, Abstract 874.
Karow Margaret
Mellis Scott
Papadopoulos Joanne
Yancopoulos George D.
Gregg, Esq. Valeta
Kemmerer Elizabeth C
Regeneron Pharmaceuticals Inc.
Smeland, Esq. Tor
Xie Xiaozhen
LandOfFree
Methods of using IL-1 antagonists to treat autoinflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using IL-1 antagonists to treat autoinflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using IL-1 antagonists to treat autoinflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4031806